A detailed history of Hbk Sorce Advisory LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Hbk Sorce Advisory LLC holds 20,811 shares of ABBV stock, worth $3.75 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
20,811
Previous 20,661 0.73%
Holding current value
$3.75 Million
Previous $3.54 Million 15.98%
% of portfolio
0.16%
Previous 0.13%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $24,576 - $29,899
150 Added 0.73%
20,811 $4.11 Million
Q2 2024

Aug 08, 2024

SELL
$154.79 - $180.76 $184,354 - $215,285
-1,191 Reduced 5.45%
20,661 $3.54 Million
Q1 2024

May 09, 2024

BUY
$159.82 - $182.1 $23,973 - $27,315
150 Added 0.69%
21,852 $3.98 Million
Q4 2023

Jan 25, 2024

SELL
$137.6 - $154.97 $78,019 - $87,867
-567 Reduced 2.55%
21,702 $3.36 Million
Q3 2023

Nov 06, 2023

BUY
$133.59 - $154.65 $89,238 - $103,306
668 Added 3.09%
22,269 $3.32 Million
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $4.17 Million - $5.19 Million
-31,458 Reduced 59.29%
21,601 $2.91 Million
Q1 2023

Aug 15, 2023

BUY
$144.61 - $166.54 $432,817 - $498,454
2,993 Added 13.86%
24,594 $3.92 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $95,297 - $109,749
659 Added 1.26%
53,059 $12.7 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $3.7 Million - $4.44 Million
26,762 Added 104.38%
52,400 $8.47 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $580,995 - $666,362
4,329 Added 20.32%
25,638 $3.44 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $916,136 - $1.16 Million
-6,657 Reduced 23.8%
21,309 $3.26 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $247,726 - $307,358
1,877 Added 7.19%
27,966 $4.53 Million
Q4 2021

Feb 15, 2022

BUY
$107.43 - $135.93 $55,541 - $70,275
517 Added 2.02%
26,089 $3.53 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $185,668 - $210,761
1,745 Added 7.32%
25,572 $2.76 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $103,947 - $115,803
988 Added 4.33%
23,827 $2.68 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $43,682 - $48,088
427 Added 1.91%
22,839 $2.47 Million
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $89,987 - $121,493
1,118 Added 5.25%
22,412 $2.4 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $39,690 - $46,583
-462 Reduced 2.12%
21,294 $1.87 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $120,913 - $161,800
1,648 Added 8.2%
21,756 $2.14 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $24,897 - $37,746
-386 Reduced 1.88%
20,108 $1.53 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $59,290 - $74,185
822 Added 4.18%
20,494 $1.82 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $41,566 - $49,975
660 Added 3.47%
19,672 $1.49 Million
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $501,422 - $640,935
7,632 Added 67.07%
19,012 $1.38 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $462,528 - $591,219
-7,040 Reduced 38.22%
11,380 $705,000
Q1 2019

May 13, 2019

BUY
$77.14 - $90.79 $2,699 - $3,177
35 Added 0.19%
18,420 $1.49 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $2,724 - $3,360
35 Added 0.19%
18,385 $1.7 Million
Q3 2018

Nov 15, 2018

BUY
$88.91 - $98.84 $35,208 - $39,140
396 Added 2.21%
18,350 $1.74 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $3,591 - $4,249
-40 Reduced 0.22%
17,954 $0
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $116,116 - $155,491
-1,262 Reduced 6.55%
17,994 $1.7 Million
Q4 2017

Feb 15, 2018

BUY
$89.56 - $98.21 $539,957 - $592,108
6,029 Added 45.58%
19,256 $1.86 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $923,905 - $1.18 Million
13,227
13,227 $1.18 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hbk Sorce Advisory LLC Portfolio

Follow Hbk Sorce Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hbk Sorce Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hbk Sorce Advisory LLC with notifications on news.